Russia is set to begin human clinical trials of a groundbreaking personalized mRNA cancer vaccine by late 2025, targeting melanoma initially and later expanding to other cancers like non-small-cell lung cancer.
Developed by the Gamaleya National Research Center for Epidemiology and Microbiology, the vaccine is designed using artificial intelligence (AI) to tailor treatment to each patient’s unique tumor genetics. This approach aims to train the immune system to recognize and eliminate cancer cells more effectively than traditional treatments.
The vaccine’s development involves analyzing a patient’s tumor DNA and utilizing AI algorithms to create a custom mRNA vaccine within about a week. Early preclinical tests showed promising results, with the vaccine slowing tumor growth and metastasis. The Russian government plans to cover the costs, providing the vaccine free of charge to eligible patients.
Trials will initially involve melanoma patients at major oncology institutes in Moscow, such as the Hertsen Research Institute and the Blokhin Cancer Center. Authorities have established new regulatory frameworks given the highly personalized nature of the vaccine, which cannot be used interchangeably between patients because it is created specifically for each individual’s tumor profile.
Experts have noted the innovation in using AI to drastically reduce the time required to design these personalized vaccines—from months down to under an hour for the computational process. While this development marks a significant advance in cancer immunotherapy, some oncologists remain cautiously optimistic, given the challenges in developing effective cancer vaccines and the need for more comprehensive data from human trials.
Summary of key points:
- Russia’s Gamaleya Center will start human trials of the AI-designed mRNA cancer vaccine by September-October 2025.
- The vaccine is personalized, made from each patient’s tumor genetics, specifically targeting melanoma initially.
- Production takes about one week using AI-driven processes.
- Early animal and limited human testing showed tumor suppression and reduced metastases.
- The Russian government will provide the vaccine free to patients.
- New regulatory pathways have been created due to the vaccine’s unique personalized nature.
- The vaccine development leverages AI to shorten the vaccine design process to under an hour.
- Trials are conducted at top Moscow oncology centers.
- There is cautious excitement but also skepticism from the broader oncology community pending further trial results.
This development represents a potentially major milestone in personalized cancer treatment in Russia, with international interest already expressed, though full clinical validation is awaited.
